13-year-old Mikhael Azman and his parents Azman Ahmad Bakri and Farahiah Ariffin, with Prader-Willi Syndrome Association of Malaysia president Azhar Talib (right). (Bernama pic) No parent is ever ...

The Food and Drug Administration approved a medication this week known as VYKAT XR to treat hyperphagia — or an incessant feeling of hunger — in kids and adults with Prader-Willi syndrome. The ...

Though the exact mechanism of action is unclear, it is believed that in patients with Prader-Willi syndrome, diazoxide choline reduces hyperphagia through activation of the adenosine triphosphate ...

Prader-Willi syndrome was associated with prolonged hospitalization and higher risk of in-hospital mortality among inpatients with COVID-19 infection. Patients with Prader-Willi syndrome (PWS) may be ...

Vykat XR is expected to be available in April 2025. The Food and Drug Administration (FDA) has approved Vykat™ XR (diazoxide choline) for the treatment of hyperphagia in adults and pediatric patients ...

Introduction: Prader-Willi syndrome (PWS) is primarily caused by a paternal microdeletion of the 15q11-q13 region, maternal uniparental disomy (mUPD) or unbalanced translocations. The MKRN3 gene, ...

The United States Food and Drug Administration (US FDA) has approved VYKAT™ XR, a significant milestone as the first approved treatment for hyperphagia in Prader-Willi syndrome (PWS). This ...